7.2 Severe Asthma Exacerbation & COPD Acute Management

7.2 Severe Asthma Exacerbation & COPD Acute Management

Pathophysiology & Clinical Divergence: Asthma vs COPD

Acute obstructive airway emergencies represent two physiologically distinct pathological processes that converge on airflow limitation, ventilation-perfusion (V/Q) mismatch, dynamic air trapping, and respiratory muscle exhaustion.

• Acute Status Asthmaticus: Driven by acute eosinophilic or allergic airway inflammation, intense smooth muscle bronchospasm, mucosal edema, and tenacious intraluminal mucus plugging. The underlying airway architecture is generally characterized by reversible bronchoconstriction, though severe attacks produce profound dynamic hyperinflation and intrinsic positive end-expiratory pressure (auto-PEEP).
• Acute Exacerbation of COPD (AECOPD): Driven by neutrophilic airway inflammation, loss of elastic parenchymal recoil (emphysema), chronic mucosal hypersecretion (chronic bronchitis), and baseline gas exchange impairment. Exacerbations are commonly triggered by viral or bacterial tracheobronchial infections, leading to dynamic expiratory collapse and acute-on-chronic carbon dioxide retention.

                      ACUTE STATUS ASTHMATICUS RESUSCITATION
  ┌───────────────────────────────────────────────────────────────────────────┐
  │ HOUR 1 DUAL INHALED THERAPY                                               │
  │  • Albuterol: 10–15 mg/h continuous nebulization OR 2.5–5 mg q20min x 3   │
  │  • Ipratropium Bromide: 0.5 mg nebulized q20min x 3 doses                 │
  ├───────────────────────────────────────────────────────────────────────────┤
  │ EARLY SYSTEMIC CORTICOSTEROIDS (Oral = IV Efficacy)                       │
  │  • Prednisone 40–60 mg PO OR Methylprednisolone 60–125 mg IV              │
  │  • 4–6 hour genomic lag time; early administration halts hospital admission│
  ├───────────────────────────────────────────────────────────────────────────┤
  │ SECOND-LINE BRONCHODILATOR RESCUE (Severe / Refractory / PEF <50%)        │
  │  • Magnesium Sulfate: 2 g IV in 100 mL D5W/NS over 15–20 minutes          │
  │  • Terbutaline: 0.25 mg SC q20min x 3 OR Epinephrine: 0.3–0.5 mg IM       │
  ├───────────────────────────────────────────────────────────────────────────┤
  │ PERI-INTUBATION INDUCTION & VENTILATION (Last Resort)                     │
  │  • Ketamine 1–2 mg/kg IV (Direct bronchodilation via NMDA / catecholamines)│
  │  • Ventilator: Low RR (8–10), small Vt (6 mL/kg), high peak flows (80 L/m)│
  └───────────────────────────────────────────────────────────────────────────┘

---

Acute Status Asthmaticus: Inhaled Bronchodilator Protocols

Inhaled Short-Acting Beta-2 Agonists (SABA): Albuterol

• Mechanism: Stimulates beta-2 adrenergic receptors on bronchial smooth muscle, activating adenylyl cyclase to increase intracellular cyclic AMP (cAMP). This activates protein kinase A, which decreases intracellular calcium concentrations, dephosphorylates myosin light chains, and produces profound smooth muscle relaxation.
• Emergency Dosing:
  • Continuous Nebulization: 10 to 15 mg/hour continuously via a large-volume nebulizer. Indicated for severe respiratory distress, marked retractions, or peak expiratory flow (PEF) <50%.
  • Intermittent Nebulization: 2.5 to 5 mg every 20 minutes for 3 doses in the first hour, then 2.5 to 5 mg every 1 to 4 hours as needed.
• Adverse Effects & Pharmacological Nuances:
  • Tachycardia & Tremor: Mediated by peripheral beta-2 vasodilation (causing reflex tachycardia) and skeletal muscle beta-2 stimulation.
  • Hypokalemia: Beta-2 receptor stimulation directly activates the Na⁺/K⁺-ATPase pump, driving potassium from the extracellular fluid into skeletal muscle cells. Serum potassium may drop by 0.5 to 1.0 mEq/L during continuous nebulization.
  • Type B Lactic Acidosis: High-dose albuterol stimulates hepatic and muscular glycogenolysis and lipolysis via beta-2 agonism, leading to accelerated aerobic glycolysis and excess pyruvate production, which is shunted to lactate. Clinicians must recognize that an isolated rising serum lactate with a stable or improving clinical exam represents drug-induced Type B lactic acidosis, rather than worsening tissue hypoxia or sepsis.

Inhaled Anticholinergics: Ipratropium Bromide

• Mechanism: Quaternary ammonium antimuscarinic agent that competitively inhibits muscarinic M3 receptors on bronchial smooth muscle and submucosal glands, blocking parasympathetic vagal bronchoconstriction and reducing mucus hypersecretion.
• Emergency Dosing: 0.5 mg nebulized every 20 minutes for 3 doses in the first hour, mixed directly with albuterol (e.g., DuoNeb).
• Guideline Direction: Adding ipratropium to albuterol during the first hour of emergency management produces synergistic bronchodilation, significantly improves FEV1, and reduces hospital admission rates by approximately 30% in moderate-to-severe exacerbations. Beyond the initial 1 to 2 hours of emergency resuscitation, routine scheduled ipratropium provides minimal additional benefit in asthma and should be discontinued upon inpatient admission.

---

Systemic Corticosteroids: Oral vs Intravenous Equivalence

Systemic corticosteroids suppress airway inflammation, reduce microvascular permeability, decrease mucus production, and—most importantly—upregulate cell-surface beta-2 adrenergic receptor expression, reversing beta-agonist receptor downregulation and tachyphylaxis.

Route of Administration & Efficacy

• Clinical Equivalence: Multiple randomized clinical trials and Cochrane systematic reviews have established that oral corticosteroids (Prednisone 40 to 60 mg PO) and intravenous corticosteroids (Methylprednisolone 60 to 125 mg IV) have identical clinical efficacy, rate of lung function recovery, and hospital length of stay.
• Pharmacokinetics: Oral prednisone and prednisolone are rapidly and completely absorbed, with oral bioavailability approaching 80% to 90%. Serum concentrations peak within 1 to 2 hours.
• Indications for IV Administration: The intravenous route should be strictly reserved for patients with active emesis, severe respiratory distress precluding the ability to swallow, altered mentation, or those requiring mechanical ventilation.
• Genomic Lag Time: Corticosteroids act primarily via cytosolic glucocorticoid receptors to alter nuclear gene transcription (inhibiting NF-kB and upregulating anti-inflammatory lipocortin-1). This genomic mechanism requires a biological lag time of 4 to 6 hours before measurable clinical improvement occurs. Therefore, corticosteroids must be administered immediately upon ED triage to impact the disposition decision at hours 3 to 6.
• Course Duration: 5 to 7 days in adults (3 to 5 days in pediatrics). Routine steroid tapering is unnecessary for courses lasting ≤7 to 10 days, as short courses do not produce clinically meaningful hypothalamic-pituitary-adrenal (HPA) axis suppression.

---

Second-Line Bronchodilator Therapies & Parenteral Beta-Agonists

Intravenous Magnesium Sulfate

• Mechanism of Action: Magnesium acts as a physiological calcium antagonist. It blocks voltage-gated calcium channels on bronchial smooth muscle cells, inhibiting calcium influx required for actin-myosin cross-bridge cycling. Furthermore, it inhibits acetylcholine release at motor nerve terminals, blunts histamine release from mast cells, and stimulates prostacyclin and nitric oxide synthesis.
• Dosing & Administration: 2 g IV (diluted in 100 mL 0.9% normal saline or 5% dextrose) infused over 15 to 20 minutes.
• Clinical Indications: Indicated for patients with severe acute asthma who present with FEV1 or PEF <50% predicted, those who fail to demonstrate substantial clinical improvement after 1 hour of aggressive inhaled bronchodilator therapy, or those presenting in extremis.
• Safety & Adverse Effects: Rapid infusion over <10 minutes can precipitate peripheral vasodilation, cutaneous flushing, transient hypotension, and bradycardia. True neuromuscular depression and hyporeflexia require serum magnesium concentrations >4 to 5 mEq/L, which are exceedingly rare with a single 2 g dose.

Parenteral Beta-Agonists: Terbutaline & Epinephrine

• Terbutaline: Selective beta-2 agonist administered as 0.25 mg subcutaneously every 20 minutes for up to 3 doses. Useful in young patients when severe bronchospasm or high inspiratory resistance prevents aerosolized medication delivery.
• Epinephrine: Administered as 0.3 to 0.5 mg IM (1 mg/mL / 1:1,000 solution) every 20 minutes for up to 3 doses. Preferred over terbutaline when acute asthma is triggered by an anaphylactic reaction or when severe dynamic hyperinflation completely limits inspiratory airflow.

---

Peri-Intubation Resuscitation & Mechanical Ventilation in Asthma

Endotracheal intubation in status asthmaticus is a life-threatening last resort associated with severe procedural complications, including pneumothorax, dynamic hyperinflation, circulatory collapse, and cardiac arrest.

Induction Pharmacology: The Primacy of Ketamine

• Ketamine (1.5 to 2.0 mg/kg IV) is the induction agent of choice for rapid sequence intubation (RSI) in severe status asthmaticus.
• Bronchodilatory Mechanisms: Ketamine produces potent, rapid bronchodilation through two distinct pathways:
  1. Sympathomimetic Stimulation: Inhibits central and peripheral neuronal catecholamine reuptake, increasing circulating epinephrine and norepinephrine, which stimulate bronchial beta-2 receptors.
  2. Direct Musculotropic Effect: Blocks L-type calcium channels and antagonizes N-methyl-D-aspartate (NMDA) receptors present on bronchial smooth muscle, directly attenuating airway tone.
• Alternative Agents: Propofol (1.5 to 2.0 mg/kg IV) also exerts mild bronchodilatory properties but can cause profound systemic vasodilation and hypotension in volume-depleted, hyperinflated patients. Etomidate (0.3 mg/kg IV) is hemodynamically neutral but lacks bronchodilatory actions.
• Neuromuscular Blockers: Rocuronium (1.2 mg/kg IV) or succinylcholine (1.5 mg/kg IV) should be selected. Older paralytics that provoke endogenous histamine release (e.g., atracurium, tubocurarine) are strictly contraindicated.

Mechanical Ventilator Strategy: Preventing Barotrauma

Patients with severe status asthmaticus have severe expiratory airflow obstruction requiring prolonged expiratory times to empty the lungs. Inadequate exhalation results in "breath stacking" and massive auto-PEEP (intrinsic PEEP), which compresses the vena cava, obliterates right ventricular preload, and causes fatal PEA cardiac arrest.

• Permissive Hypercapnia: The goal is not normal arterial blood gases, but preventing lung trauma. Clinicians should tolerate respiratory acidosis (pH ≥7.15 to 7.20, PaCO2 60 to 90 mmHg) to avoid excessive ventilation.
• Ventilator Settings:
  • Low respiratory rate: 8 to 12 breaths/minute.
  • Small tidal volumes: 6 to 8 mL/kg predicted body weight.
  • High peak inspiratory flow rates: 70 to 80 L/minute (shortens inspiratory time, maximizing expiratory time).
  • Extended inspiratory-to-expiratory ratio: I:E ratio of 1:3, 1:4, or 1:5.
  • Low external PEEP: 0 to 5 cm H2O (external PEEP must never exceed 80% of auto-PEEP).

---

Acute Exacerbation of COPD (AECOPD) Resuscitation

Controlled Oxygen Delivery: Target SpO2 88% to 92%

Administering uncontrolled high-concentration supplemental oxygen (e.g., 100% via non-rebreather mask) to patients experiencing an acute COPD exacerbation can precipitate profound hypercapnia, severe respiratory acidosis, obtundation, and death.

                    TRIPLE MECHANISMS OF O2-INDUCED HYPERCAPNIA
  ┌───────────────────────────────────────────────────────────────────────────┐
  │ 1. REVERSAL OF HYPOXIC PULMONARY VASOCONSTRICTION (HPV) [Dominant]        │
  │    High alveolar O2 dilates pulmonary arterioles supplying non-ventilated │
  │    alveoli ──► Drastically increases dead space and V/Q mismatch         │
  ├───────────────────────────────────────────────────────────────────────────┤
  │ 2. THE HALDANE EFFECT [Contributory]                                      │
  │    Deoxygenated hemoglobin binds CO2 with higher affinity than oxyhemoglobin│
  │    Oxygenation displaces CO2 from carbaminohemoglobin into plasma ──► ↑PaCO2│
  ├───────────────────────────────────────────────────────────────────────────┤
  │ 3. BLUNTING OF HYPOXIC VENTILATORY DRIVE [Minor]                          │
  │    Mild suppression of peripheral carotid chemoreceptor firing rate        │
  └───────────────────────────────────────────────────────────────────────────┘

Guidelines mandate controlled oxygen titration using a Venturi mask or low-flow nasal cannula targeting an arterial oxygen saturation (SpO2) of 88% to 92% (PaO2 ~60 to 70 mmHg).

Systemic Corticosteroids: The Landmark REDUCE Trial

• The REDUCE Trial (2013): The landmark Reduction in the Use of Corticosteroids in Exacerbated COPD (REDUCE) trial evaluated 314 patients presenting to the emergency department with acute COPD exacerbations, comparing 5 days of oral prednisone (40 mg daily) against the traditional 14 days of oral prednisone (40 mg daily).
• Findings: The 5-day regimen was completely non-inferior to the 14-day regimen regarding the rate of recurrent COPD exacerbation at 6 months (35.9% vs 36.8%), hospital length of stay, and all-cause mortality, while significantly reducing cumulative glucocorticoid exposure, secondary infections, and hyperglycemic adverse events.
• Guideline Standard: GOLD guidelines endorse Prednisone 40 mg PO once daily for exactly 5 days as the gold standard for acute COPD exacerbations.

Antibiotic Indications: The Anthonisen Criteria

Bacterial tracheobronchial infections account for 50% to 70% of COPD exacerbations. Common pathogens include Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis, and, in patients with severe underlying disease, Pseudomonas aeruginosa.

• Empirical Regimens (5-Day Duration):
  • Azithromycin: 500 mg PO on day 1, then 250 mg PO daily on days 2 to 5.
  • Doxycycline: 100 mg PO twice daily for 5 days.
  • Amoxicillin-Clavulanate: 875/125 mg PO twice daily for 5 days.
  • Pseudomonas Risk (FEV1 <30%, frequent hospitalizations, chronic oral steroids): Ciprofloxacin 500 mg PO BID or Levofloxacin 500 mg PO daily for 5 to 7 days.

Non-Invasive Positive Pressure Ventilation (BiPAP)

Non-invasive positive pressure ventilation (BiPAP) is the first-line ventilatory support modality for acute hypercapnic respiratory failure (defined as respiratory acidosis: arterial pH <7.35 and PaCO2 >45 mmHg).

• Physiological Benefits: Inspiratory positive airway pressure (IPAP, 10 to 15 cm H2O) augments tidal volume and unloads fatigued diaphragmatic muscles, decreasing the work of breathing. Expiratory positive airway pressure (EPAP, 4 to 5 cm H2O) counteracts intrinsic auto-PEEP, recruits collapsed alveoli, and improves gas exchange.
• Outcomes: BiPAP reduces endotracheal intubation rates by >60% and significantly lowers in-hospital mortality compared to standard medical therapy alone.